Objective To explore the efficacy and safety of eltrombopag combined with cyclosporin in the treatment of patients with refractory immune thrombocytopenia (ITP).
Methods According to the different therapeutic plans, a total of 39 patients with refractory ITP were divided into experimental group with 16 cases (treated with eltrombopag and cyclosporin) and control group with 23 cases (treated with cyclosporin).Platelet count of patients before treatment and 3, 9 months after treatment were recorded, therapeutic effect and effective rate were evaluated, and the adverse reactions of drugs and efficacy during treatment were observed and followed up.
Results After 3 months of treatment, the total effective rate of the control group and the experimental group was 69.57% and 81.25% respectively, and there was no significant difference between two groups (P>0.05).After 9 months of treatment, the total effective rate of the control group and the experimental group was 34.78% and 62.50% respectively, and there was a significant difference between the two groups (P < 0.05).The total incidence of adverse reactions in the experimental group and the control group was 37.50%(6/16) and 39.13%(9/23) respectively, and there was no significant difference between two groups (P>0.05).
Conclusion Eltrombopag combined with cyclosporine can increase the platelet count of patients with refractory ITP and improve the clinical symptoms, and has higher safety and compliance.
DownLoad: